Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25628747 | 1.00 | EPHX2 (0.42) | EPHX2NAMPTKMT2ACNR2TLR9 | |
| SCHEMBL22874736 | 1.00 | EPHX2 (0.42) | EPHX2NAMPTKMT2ACNR2TLR9 | |
| SCHEMBL25811304 | 0.91 | PIK3CD (0.40) | EPHX2NAMPTKMT2ACNR2TLR9 | |
| SCHEMBL26288084 | 0.91 | PIK3CD (0.40) | EPHX2NAMPTKMT2ACNR2TLR9 | |
| SCHEMBL17540496 | 0.91 | EPHX2 (0.44) | EPHX2CNR2RECQLPOLBHPGD | |
| SCHEMBL26296771 | 0.91 | PIK3CD (0.40) | EPHX2NAMPTKMT2ACNR2TLR9 | |
| SCHEMBL17540510 | 0.90 | POLB (0.48) | KMT2ACNR2IDH1RECQLPOLB | |
| SCHEMBL22098000 | 0.88 | HPGD (0.39) | KMT2AIDH1RECQLPOLBHPGD | |
| SCHEMBL22874738 | 0.88 | NAMPT (0.40) | EPHX2NAMPTKMT2ACNR2TLR9 | |
| SCHEMBL12385902 | 0.81 | KMT2A (0.46) | EPHX2NAMPTKMT2ACNR2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | EPHX2 4282/4885NAMPT 4690/4885KMT2A 765/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | EPHX2 4118/4885NAMPT 4578/4885KMT2A 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.